Keyword Search
Sessions Were Renumbered as of May 19.
Legend:
CC-W = McCormick Place Convention Center, West Building, CC-N = McCormick Place Convention Center, North Building
H = Hilton Chicago, UC= Conference Chicago at University Center
* = applied session ! = JSM meeting theme
|
Keyword Search Criteria: Maximum tolerated dose returned 10 record(s)
|
|
Monday, 08/01/2016
|
A Bayesian Adaptive Design in Cancer Phase I Trials Using Dose Combinations in the Presence of a Baseline Covariate
Sungjin Kim; Mourad Tighiouart, Cedars-Sinai Medical Center; Marcio Diniz, Cedars-Sinai Medical Center
|
Bayesian Adaptive Designs Using Copula-Type Models in Phase I Cancer Trials Using Drug Combination
Galen Cook-Wiens, Cedars-Sinai Medical Center; Mourad Tighiouart, Cedars-Sinai Medical Center; Marcio Diniz, Cedars-Sinai Medical Center; Andre Rogatko, Cedars-Sinai Medical Center
|
Dose Finding for Drug Combination in Early Cancer Phase I Trials using Conditional Continual Reassessment Method
Quanlin Li; Mourad Tighiouart, Cedars-Sinai Medical Center; Marcio Diniz, Cedars-Sinai Medical Center
|
Consideration of the T-Statistic Adaptive Dose-Finding Design for Estimating Maximum Tolerated Dose
James Bolognese, Cytel
9:05 AM
|
Benefit-Risk Analysis for Dose-Escalation Trial
Hiya Banerjee
9:50 AM
|
A Simple Bayesian Design to Identify Maximum Tolerated Dose Contour for Drug Combination Trials
Liangcai Zhang, Rice University; Ying Yuan, MD Anderson Cancer Center
2:20 PM
|
Use of Bayesian Methods in Dose-Escalation Studies
Mani Lakshminarayanan, Pfizer
2:50 PM
|
|
Wednesday, 08/03/2016
|
Adaptive Estimation of Personalized Maximum Tolerated Doses in Cancer Phase I Clinical Trials According to All Toxicities and Individual Characteristics
Zhengjia Chen, Emory University; Zheng Li, Penn State University; Ying Yuan, MD Anderson Cancer Center; Michael Kutner, Emory University; Taofeek Owonikoko, Emory University; Walter J. Curran, Emory University; Jeanne Kowalski, Emory University
|
Adaptive Estimation of Personalized Maximum Tolerated Doses in Cancer Phase I Clinical Trials According to All Toxicities and Individual Characteristics
Zhengjia Chen, Emory University; Zheng Li, Penn State University; Ying Yuan, MD Anderson Cancer Center; Michael Kutner, Emory University; Taofeek Owonikoko, Emory University; Walter J. Curran, Emory University; Jeanne Kowalski, Emory University
8:45 AM
|
|
|
